AU2019234670B2 - Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof - Google Patents

Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof Download PDF

Info

Publication number
AU2019234670B2
AU2019234670B2 AU2019234670A AU2019234670A AU2019234670B2 AU 2019234670 B2 AU2019234670 B2 AU 2019234670B2 AU 2019234670 A AU2019234670 A AU 2019234670A AU 2019234670 A AU2019234670 A AU 2019234670A AU 2019234670 B2 AU2019234670 B2 AU 2019234670B2
Authority
AU
Australia
Prior art keywords
methyl
pyridin
carboxamide
fluoroimidazo
cyclopropylimidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019234670A
Other languages
English (en)
Other versions
AU2019234670A1 (en
Inventor
David Edward EHMANN
John Mark Ellard
Sarah Jocelyn FINK
Thomas Allen MILLER
Nikolaos PAPAIOANNOU
Alastair Rae
Gerald Wayne SHIPPS Jr.
Jeremy Mark Travins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2019234670A1 publication Critical patent/AU2019234670A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: SHIRE HUMAN GENETIC THERAPIES, INC.
Application granted granted Critical
Publication of AU2019234670B2 publication Critical patent/AU2019234670B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2019234670A 2018-03-13 2019-03-12 Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof Active AU2019234670B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862642376P 2018-03-13 2018-03-13
US62/642,376 2018-03-13
US201862757728P 2018-11-08 2018-11-08
US62/757,728 2018-11-08
PCT/US2019/021897 WO2019178129A1 (en) 2018-03-13 2019-03-12 Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Publications (2)

Publication Number Publication Date
AU2019234670A1 AU2019234670A1 (en) 2020-09-03
AU2019234670B2 true AU2019234670B2 (en) 2023-11-23

Family

ID=65904618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019234670A Active AU2019234670B2 (en) 2018-03-13 2019-03-12 Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Country Status (9)

Country Link
US (3) US10730874B2 (enExample)
EP (1) EP3765459A1 (enExample)
JP (2) JP7590183B2 (enExample)
KR (1) KR20200143376A (enExample)
CN (1) CN112135825A (enExample)
AU (1) AU2019234670B2 (enExample)
CA (1) CA3093802A1 (enExample)
TW (1) TWI834641B (enExample)
WO (1) WO2019178129A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4494698A3 (en) * 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
TW202045011A (zh) * 2019-02-28 2020-12-16 瑞士商先正達農作物保護公司 具有含硫取代基之殺有害生物活性雜環衍生物
JPWO2020204112A1 (enExample) 2019-04-01 2020-10-08
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
EP4136091B1 (en) 2020-04-17 2025-05-28 Takeda Pharmaceutical Company Limited Forms and compositions of inhibitors of plasma kallikrein
WO2021211938A1 (en) 2020-04-17 2021-10-21 Shire Human Genetic Therapies, Inc. Solid forms of inhibitors of plasma kallikrein
EP4223755A4 (en) 2020-09-30 2025-05-14 Sumitomo Chemical Company, Limited Heterocyclic compound and composition containing it for controlling harmful arthropods
WO2022197755A1 (en) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Imidazopyridinyl inhibitors of plasma kallikrein
US20240382482A1 (en) * 2021-03-17 2024-11-21 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors
US20240226106A1 (en) 2021-03-17 2024-07-11 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein
EP4585265A3 (en) 2021-03-17 2025-10-15 Takeda Pharmaceutical Company Limited Heteroaryl inhibitors of plasma kallikrein
US20240199613A1 (en) * 2021-03-17 2024-06-20 Takeda Pharmaceutical Company Limited Polycyclic inhibitors of plasma kallikrein
WO2024059186A1 (en) 2022-09-15 2024-03-21 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
TW202500130A (zh) * 2023-05-09 2025-01-01 美商安進公司 用作１５－前列腺素脫氫酶調節劑之５，６－稠合和６，６－稠合的雙環醇和醚及組成物
WO2025067464A1 (zh) * 2023-09-28 2025-04-03 杭州圣域生物医药科技有限公司 杂芳基化合物、其中间体、制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011209A1 (en) * 2014-07-16 2016-01-21 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US20160200704A1 (en) * 2013-12-30 2016-07-14 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018011628A1 (en) * 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPH0832707B2 (ja) 1986-02-05 1996-03-29 富山化学工業株式会社 新規なセフアロスポリン類およびその塩
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
ATE216247T1 (de) 1991-05-20 2002-05-15 Rhone Poulenc Rorer Internat H Aromatische oligomere verbindungen als imitatoren bioaktives makromoleküle
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
JP2000256286A (ja) 1999-03-11 2000-09-19 Kaken Pharmaceut Co Ltd アルキルアミン誘導体
KR20020088406A (ko) 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
AU2004255913B2 (en) 2003-07-09 2007-10-11 Takeda Pharmaceutical Company Limited Organosilicon compounds and their use
EP1758579A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
WO2006091898A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
WO2007009236A1 (en) 2005-07-20 2007-01-25 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
EP1981519B1 (en) * 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2051707B1 (en) * 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP1908762A2 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds
EP1908471A1 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
WO2008059854A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
CN101842098A (zh) 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
KR100994115B1 (ko) 2008-08-18 2010-11-15 삼성모바일디스플레이주식회사 광효율 개선층을 구비한 유기 발광 소자
US20100160369A1 (en) 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
AU2010239188B2 (en) 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
CA2760778A1 (en) 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
TW201109327A (en) 2009-05-28 2011-03-16 Otsuka Pharma Co Ltd Heterocyclic compound
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
JP2012111731A (ja) 2010-11-26 2012-06-14 Otsuka Pharmaceut Co Ltd 医薬
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2697196A1 (en) * 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
WO2013052526A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
WO2013081094A1 (ja) 2011-11-30 2013-06-06 東レ株式会社 イミダゾ［１，２－ａ］ピリジン誘導体及びその医薬用途
MX352861B (es) 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
HRP20170411T1 (hr) 2012-03-02 2017-06-16 Genentech, Inc. Amido spirocilični amidni i sulfonamidni derivati
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
WO2015063093A1 (de) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
US9624170B2 (en) 2013-12-26 2017-04-18 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors
US10266515B2 (en) 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP3152206A1 (en) 2014-06-06 2017-04-12 Biogen MA Inc. Atx modulating agents
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
EP3578541B1 (en) 2015-04-17 2025-05-28 Corteva Agriscience LLC Compositions comprising molecules having pesticidal utility, and processes related thereto
WO2017001936A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2017001926A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc Therapeutic inhibitory compounds
WO2017098328A2 (en) 2015-12-11 2017-06-15 Lifesci Phamaceuticals, Inc. Therapeutic inhibitory compounds
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
ME03794B (me) 2016-05-31 2021-04-20 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
WO2018015818A2 (en) 2016-07-15 2018-01-25 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
JP2019529484A (ja) * 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
US11111245B2 (en) 2017-02-01 2021-09-07 Aucentra Therapeutics Pty Ltd Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CN110678466B (zh) 2017-03-30 2023-01-31 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类
WO2018229543A2 (en) 2017-06-14 2018-12-20 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
EP4494698A3 (en) 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
WO2021004535A1 (en) 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Cinnolines as inhibitors of hpk 1
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
CN114605401B (zh) 2020-04-28 2023-08-22 江南大学 一类含氧五元杂环化合物、合成方法、药物组合物及用途
US20240199612A1 (en) 2021-02-23 2024-06-20 Shire Human Genetic Therapies, Inc. Imidazopyridinyl inhibitors of plasma kallikrein
WO2022197755A1 (en) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Imidazopyridinyl inhibitors of plasma kallikrein
EP4585265A3 (en) 2021-03-17 2025-10-15 Takeda Pharmaceutical Company Limited Heteroaryl inhibitors of plasma kallikrein
US20240226106A1 (en) 2021-03-17 2024-07-11 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein
US20240199613A1 (en) 2021-03-17 2024-06-20 Takeda Pharmaceutical Company Limited Polycyclic inhibitors of plasma kallikrein
US20240382482A1 (en) 2021-03-17 2024-11-21 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160200704A1 (en) * 2013-12-30 2016-07-14 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2016011209A1 (en) * 2014-07-16 2016-01-21 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018011628A1 (en) * 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds

Also Published As

Publication number Publication date
CA3093802A1 (en) 2019-09-19
JP7590183B2 (ja) 2024-11-26
US10730874B2 (en) 2020-08-04
US20230078513A1 (en) 2023-03-16
KR20200143376A (ko) 2020-12-23
TW202003513A (zh) 2020-01-16
JP2024012697A (ja) 2024-01-30
US12441724B2 (en) 2025-10-14
JP2021517893A (ja) 2021-07-29
US11352356B2 (en) 2022-06-07
CN112135825A (zh) 2020-12-25
US20190284182A1 (en) 2019-09-19
EP3765459A1 (en) 2021-01-20
AU2019234670A1 (en) 2020-09-03
WO2019178129A1 (en) 2019-09-19
US20200317667A1 (en) 2020-10-08
TWI834641B (zh) 2024-03-11

Similar Documents

Publication Publication Date Title
AU2020274083B9 (en) FGFR inhibitors and methods of use thereof
TWI834641B (zh) 血漿激肽釋放素抑制劑及其用途
AU2021257988B2 (en) Purinones as ubiquitin-specific protease 1 inhibitors
CN114728962B (zh) 血浆激肽释放酶抑制剂及其用途
AU2014348191B2 (en) Tetrahydroquinoline compositions as BET bromodomain inhibitors
US9550737B2 (en) TNF -α modulating benzimidazoles
AU2014362231B2 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US20210032251A1 (en) Heterobicyclic amides as inhibitors of cd38
WO2023091726A1 (en) Inhibitors of cyclin‑dependent kinase 12 (cdk12)
AU2018278928A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CA2935867A1 (en) Heteroaryls and uses thereof
US9150592B2 (en) Heterocyclic nuclear hormone receptor modulators
WO2026067385A1 (zh) 新fgfr3抑制剂化合物
IL323942A (en) Sarm1 modulators, preparations, and uses thereof
EP4587434A1 (en) N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
US20260138956A1 (en) Novel compounds and uses thereof
CN119302952A (zh) 含苯基取代的二氢萘啶类化合物的药物制剂与用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): SHIRE HUMAN GENETIC THERAPIES, INC.

FGA Letters patent sealed or granted (standard patent)